In the general news, the State of the Union speech was uneventful. In Atlanta, a bumbling government allowed 2-inches of snow to strand thousands of cars on the freeways for days. In Wall Street, the stock markets finished down, with the worst January performance since 2009. Lastly, the Super Bowl was won by the Denver Broncos.
In healthcare business news, earnings seasons continued, with ALXN spiking on Soliris sales, and PFE continuing to struggle. STJ will stay in the renal denervation market. BIIB reported that drug pricing power is reducing as the numerous therapies for MS hit the market and cannibalize one another. AZN is cutting more jobs, and JNJ announced that it will hire Dr. Krumholz’s team at Yale for consulting on clinical data (Krumholz also heads up PCORI).
On the data front, new studies in PLOS added to NEJM reports that the popular “Low T” testosterone drugs double or triple the risk of heart attack in men over 65.
From the FDA, the agency will study the MI risk from topical testosterone replacement drugs, such as Axiron (LLY) and Androgel (ABBV). Also Vanda (VNDA) received approval for the new sleep aid drug Hetlioz.